Last year, over 35 million square feet of lab and research and development properties were under construction globally, a striking surge in new infrastructure that might suggest a booming, insatiable demand. Yet, this aggressive expansion occurred even as vacancy rates across tracked markets climbed to 23.1%, and global lab and cGMP rents declined 1.7% year-over-year, according to Cushman & Wakefield. This simultaneous surge in supply and softening of market fundamentals presents a perplexing paradox for investors and developers.
Global biopharma construction and investment are indeed surging, driven by sustained innovation and capital inflow. However, the market signals, particularly declining rents and rising vacancy rates, indicate a potential oversupply in some regions. This tension creates a critical challenge: discerning the true key factors for success in regional biopharma hubs as 2026 unfolds, and understanding where capital is genuinely creating value versus merely swelling an already saturated market.
While capital continues to flow into the life sciences sector, a more discerning approach to regional development and investment will be critical to avoid significant losses in emerging or overbuilt markets. The data suggests that companies developing general-purpose lab space are facing a measurable risk of oversupply and diminishing returns, demanding a meticulous re-evaluation of investment strategies.
The High Stakes of Biopharma Growth
The European deep tech and life sciences spinouts alone are collectively valued at approximately $398 billion, having created over 167,000 jobs across more than 7,300 companies, as detailed in the European Life Sciences Ecosystems: Sector Guide 2026 by CBRE. The immense economic footprint of European deep tech and life sciences spinouts, valued at approximately $398 billion and having created over 167,000 jobs across more than 7,300 companies, profoundly impacts global economies, influencing job markets and technological advancements far beyond the laboratory.
Further demonstrating this vitality, global R&D investment sales climbed to $13.5 billion in 2025, marking a significant 28% increase year-over-year, according to Cushman & Wakefield. Concurrently, venture capital funding held steady at $49 billion, a figure notably supported by strong momentum in the Asia-Pacific region. Global R&D investment sales climbing to $13.5 billion in 2025 and venture capital funding holding steady at $49 billion, despite the broader market softening, indicate a sustained investor confidence in the sector's long-term potential, though perhaps with a shift in focus.
The sheer scale of economic activity and sustained investment underscores the high stakes in understanding what makes a biopharma hub thrive amidst evolving market dynamics. It reveals that while some areas of the market may be facing oversupply, capital is increasingly flowing into strategic acquisitions and specialized projects within the biopharma sector, rather than fueling a broad-based expansion of generic lab infrastructure. Selective investment, flowing into strategic acquisitions and specialized projects within the biopharma sector rather than fueling a broad-based expansion of generic lab infrastructure, highlights a growing discernment among those deploying capital.
Established Ecosystems and Sustained Investment
San Diego consistently ranks as a top three Life Sciences market in the U.S. a testament to its long-standing infrastructure and robust scientific community, according to San Diego Business. Such established ecosystems provide a fertile ground for innovation, attracting both talent and capital due to their proven track record and extensive networks of academic institutions, research facilities, and existing biopharma companies.
In Europe, venture capital investment into life sciences rebounded strongly in 2025, with total healthcare and life sciences VC volumes reaching €13.2 billion, an increase of 2.8% on 2024, as reported by CBRE's Global Life Sciences Atlas. The strong rebound in venture capital investment into life sciences in 2025, with total healthcare and life sciences VC volumes reaching €13.2 billion, particularly within established European hubs, suggests that investors continue to favor regions with existing strengths and demonstrated resilience, rather than venturing into speculative, undeveloped markets.
Established reputations and a proven track record of innovation create a gravitational pull for further investment and talent, solidifying a region's status as a top-tier hub. This phenomenon illustrates that while global R&D investment sales climbed 28% to $13.5 billion and VC funding held steady at $49 billion, the simultaneous rise in vacancy suggests that capital is increasingly flowing into strategic acquisitions and specialized projects within these proven regions, rather than fueling a broad-based expansion of generic lab infrastructure in unproven areas.
Targeted Manufacturing and Job Creation
Amgen will expand its biologics manufacturing operation in Holly Springs, North Carolina, a move projected to create 370 additional jobs and involve a substantial investment of $1 billion, according to EDPNC. Amgen's commitment to expand its biologics manufacturing operation in Holly Springs, North Carolina, creating 370 additional jobs and involving a substantial investment of $1 billion, exemplifies a strategic focus on tangible production capacity, rather than just research infrastructure.
Similarly, Johnson & Johnson plans to create 420 jobs in Wilson County, North Carolina, with an investment exceeding $2 billion for a new pharmaceutical manufacturing campus. Substantial, multi-billion dollar manufacturing investments by Amgen, Johnson & Johnson, and Reckitt in North Carolina, despite broader market softening, indicate that the future of biopharma real estate lies in specialized production facilities within established hubs, not speculative R&D lab construction.
Further reinforcing this trend, Reckitt will invest $145.59 million in a new manufacturing facility, also in Wilson, North Carolina, creating 289 new jobs. Massive, specific manufacturing commitments, such as Reckitt's $145.59 million investment in a new manufacturing facility creating 289 new jobs, highlight the importance of direct, large-scale investment in physical infrastructure and job creation for robust regional economic growth. Specialized investment, such as Reckitt's new manufacturing facility, contrasts sharply with the broader market's oversupply of general lab space, pointing to a strategic pivot towards high-value production.
Global Dynamics and Oversupply Risks
Beijing and Shanghai together lead global life sciences construction activity, with over 13.7 million square feet of lab and R&D properties under construction, as reported by CBRE. The intense concentration of new development in specific global regions, with Beijing and Shanghai leading global life sciences construction activity with over 13.7 million square feet of lab and R&D properties under construction, highlights ambitious expansion plans, particularly in emerging markets.
However, this construction boom in developing hubs occurs against a backdrop of rising global vacancy rates and declining rents in general lab and cGMP spaces. The concentrated construction boom in specific global regions, coupled with softening market fundamentals elsewhere, indicates a growing risk of oversupply in certain segments of the biopharma real estate market, especially for generic lab space. While investment is high, some developing hubs may be particularly vulnerable to oversupply, while established markets might be better positioned to absorb specialized investments.
The simultaneous surge of over 35 million sq. ft. of lab/R&D properties under construction globally, even as vacancy rates across tracked markets climbed to 23.1% and global lab and cGMP rents declined 1.7% year-over-year, is a counterintuitive finding. It points to a misallocation of capital towards general-purpose lab space, creating an unsustainable situation where developers in some regions face diminishing returns as they add to an already saturated supply.
Navigating the Evolving Landscape
As the biopharma real estate market undergoes this significant rebalancing, stakeholders must prioritize strategic planning over speculative growth. Regions aiming for sustainable success should focus on building upon unique local strengths, whether that means specialized manufacturing capabilities, access to specific talent pools, or strong academic research ties. A 'build it and they will come' mentality, particularly for general-purpose lab space, appears increasingly risky given current market indicators.
Careful market analysis, scrutinizing demand for specialized facilities rather than broad R&D infrastructure, is paramount. Investors must conduct thorough due diligence to differentiate between genuine demand drivers and areas already approaching saturation. The multi-billion dollar manufacturing investments by Amgen, Johnson & Johnson, and Reckitt in North Carolina, despite broader market softening, indicate that the future of biopharma real estate lies in specialized production facilities within established hubs, not speculative R&D lab construction.
Strategic planning, focusing on unique regional strengths, and careful market analysis are paramount for sustainable growth in the evolving biopharma landscape, moving beyond a simplistic 'build it and they will come' mentality. This approach will help mitigate the risks associated with the global construction boom and ensure that capital is directed towards projects with a higher likelihood of long-term viability and impact.
Common Questions on Biopharma Hub Development
What makes a biopharma hub successful?
A successful biopharma hub typically combines robust academic research institutions, a skilled talent pipeline, access to venture capital, and supportive government policies. It also often features a strong network of existing companies that foster collaboration and innovation, creating a synergistic environment for growth.growth and specialized development.
How do regional biopharma clusters grow?
Regional biopharma clusters grow through a combination of organic expansion from existing companies and the attraction of new enterprises, often driven by anchor institutions like major universities or research hospitals. These clusters benefit from localized expertise, shared infrastructure, and a concentrated workforce, which together create a self-reinforcing cycle of development and investment.
What challenges do regional biopharma hubs face in 2026?
In 2026, regional biopharma hubs face challenges including potential oversupply of general lab space, intense competition for specialized talent, and the need for significant, targeted capital investment in manufacturing rather than speculative R&D. Adapting to these dynamics requires hubs to differentiate their offerings and align with specific industry demands.
The Future of Biopharma Hubs: Strategic Differentiation
The biopharma real estate market stands at a crossroads, marked by both surging investment and signs of oversupply in general lab spaces. The evidence points to a clear bifurcation: while speculative development of generic R&D facilities faces increasing headwinds, targeted investments in specialized manufacturing within established, resilient regional hubs are proving to be the true drivers of sustainable growth and job creation.
Understanding the interplay of capital, infrastructure, talent, and market demand is crucial for developing resilient and successful biopharma ecosystems that can withstand market fluctuations. The global construction boom, particularly in regions like Beijing and Shanghai, highlights the need for careful consideration of local demand versus global supply, preventing a race to build undifferentiated assets.
The future of biopharma hubs will be defined by strategic differentiation, a realistic assessment of market demand, and targeted investments that build upon existing strengths, rather than simply chasing broad sector growth. By Q3 2026, developers who prioritized specialized facilities in proven markets, like those attracting Amgen's $1 billion investment in North Carolina, will likely see stronger returns compared to those who bet on a general market expansion in less differentiated locales.
